LONGEVA.

HGF: adverse events in a clinical study

In Ido and colleagues’ open-label study, four patients with severe liver failure received intravenous recombinant HGF for 12–14 days. Blood pressure decreased during infusions in three patients and recovered after administration ended. [1]

This small study in critically ill patients cannot establish adverse-reaction frequencies in broader populations. Its findings do not establish safety of a particular laboratory HGF batch or other routes. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Blood pressure decrease during infusionsFour patients with severe liver failure, intravenous recombinant HGF for 12–14 daysObserved in 3 of 4 patients (75% in this small study; on the pharmacy scale — very common, ≥10%); blood pressure recovered after administration ended[1]

References

  1. Ido A et al. (2011). Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety https://doi.org/10.1186/1479-5876-9-55.